Pembrolizumab
(Synonyms: 派姆单抗,帕博利珠单抗,Lambrolizumab; MK-3475) 目录号 : GC19531
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体，已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性，并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。
Cas No.:1374853-91-4
Sample solution is provided at 25 µL, 10mM.
Pembrolizumab, an anti–programmed death-1 monoclonal antibody, has demonstrated clinically significant anti-tumor activity with acceptable safety in patients with advanced solid cancers and was approved by the U.S. FDA for the treatment of advanced melanoma, NSCLC, head and neck squamous cell cancer, and other malignant tumors.[1]
In vitro study demonstrated that pembrolizumab had a greater effect on PD-1 expression in CD4+CD25- T cells which expressed most of the PD-1, and that are comprised of non-Treg and/or non-activated T cells. However, pembrolizumab did not affect the expression levels of Treg-related markers, including cytotoxic T lymphocyte antigen-4 (CTLA-4), CD15s, latency-associated peptide (LAP) and Ki-67 as well as the levels of FoxP3+/-Helios+/- Treg subsets in both cohorts.[2]
In vivo study of pembrolizumab indicated that in Onco-Humanized NSG mice, pembrolizumab could inhibit tumor growth, not only in CDX but also in various PDX tumor models. Results showed that the efficacy of pembrolizumab is dependent on the engraftment of an adaptive human immune system in Onco-Humanized NSG mice, specifically hCD8+ T cells. Furthermore, pembrolizumab increased both CD4+ and CD8+ T-cell numbers in the blood of the 2 NSCLC Onco-Humanized NSG models but decreased both CD4+ and CD8+ T-cell numbers in the blood of the TNBC Onco-Humanized NSG model.[3]
References:
[1]. Mo DC, et al. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol. 2021 Feb;91:107281.
[2]. Toor SM, et al. In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol. 2018 Feb;191(2):189-197.
[3]. Wang M, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 Mar;32(3):1537-1549.
Pembrolizumab 是一种抗程序性死亡 1 单克隆抗体，已在晚期实体癌患者中证明具有临床显着的抗肿瘤活性和可接受的安全性，并已被美国 FDA 批准用于治疗晚期黑色素瘤、NSCLC、头颅和脑肿瘤。颈部鳞状细胞癌等恶性肿瘤。[1]
体外研究表明，派姆单抗对 CD4+CD25-T 细胞中的 PD-1 表达有更大的影响，这些细胞表达大部分 PD-1，并且由非 Treg 和/或未激活的 T 细胞组成。然而，pembrolizumab 不影响 Treg 相关标志物的表达水平，包括细胞毒性 T 淋巴细胞抗原 4 (CTLA-4)、CD15s、潜伏相关肽 (LAP) 和 Ki-67 以及 FoxP3+/- Helios+/- 两个队列中的 Treg 子集。[2]
pembrolizumab 的体内研究表明，在 Onco-Humanized NSG 小鼠中，pembrolizumab 可以抑制肿瘤生长，不仅在 CDX 中，而且在各种 PDX 肿瘤模型中。结果表明，pembrolizumab 的疗效取决于适应性人类免疫系统在 Onco-Humanized NSG 小鼠中的植入，特别是 hCD8+ T 细胞。此外，pembrolizumab 增加了 2 个 NSCLC Onco-Humanized NSG 模型血液中的 CD4+ 和 CD8+ T 细胞数量，但减少了 TNBC Onco-Humanized NSG 模型血液中的 CD4+ 和 CD8+ T 细胞数量。[ 3]
| Cell experiment [1]: | |
|
Cell lines |
Peripheral blood mononuclear cells (PBMC) |
|
Preparation Method |
PBMC were isolated from fresh whole blood. PBMC were suspended at 2 x 106 cells/well in 2 ml complete medium (RPMI-1640 supplemented with 2 mM L-glutamine, 10% FCS and 1% penicillin/streptomycin); 24-well non-treated culture plates were precoated with plate-bound 2 μg/ml anti-CD3 antibody and 2 μg/ml anti-CD28 antibody for 2.5 h at 37℃. |
|
Reaction Conditions |
PBMC were either plated as‘non-activated’ in non-coated wells or ‘activated’ in precoated wells. Plated cells were then treated with anti-PD-1 monoclonal antibody, pembrolizumab, at 2 μg/ml and were incubated for 24 h in a humidified incubator at 37℃ and 5% CO2. |
|
Applications |
Pembrolizumab treatment could reduce PD-1 expression significantly in CD4+ T cells in non-activated and activated PBMC. Pembrolizumab treatment resulted in a significant reduction in PD-1 expression in both CD4+CD25+ T cells and CD4+CD25- T cells. |
| Animal experiment [2]: | |
|
Animal models |
NSG mice; Humanized NSG mice |
|
Preparation Method |
Humanized NSG mice were generated by intravenous injection of 105 human CD34+ (hCD34+) HPSCs into 3-week-old female NSG mice, 4 h post-140 cGy total body irradiation using the RS-2000 irradiator. Humanized NSG mice that had over 25% hCD45+ cells in the peripheral blood were considered as engrafted and humanized. Then patient-derived tumors were finely minced and loaded into 1-cc syringes with 14-gauge needles. Depending on the tumor model, 20–40 µl of homogenized tumor tissue was inoculated subcutaneously at the right flank of mice while under anesthesia. |
|
Dosage form |
10 mg/kg i.p. for the first dose, followed by 5 mg/kg, i.p. dosage on day 5, 10, 15, 20, and 25. |
|
Applications |
Pembrolizumab treatment significantly decreased PD-1+ cell detection in hCD45+ cells in tumor models. But the percentage of PD-L1+ cells in hCD45+ or hCD45- cell populations was not affected by pembrolizumab treatment. Moreover, pembrolizumab treatment obviously delayed TNBC CDX growth compared with the vehicle control group and inhibited tumor growth in both TNBC and NSCLC PDX Onco-Humanized NSG models. |
|
References: [1]. Toor SM, et al. In-vitro effect of pembrolizumab on different T regulatory cell subsets. Clin Exp Immunol. 2018 Feb;191(2):189-197. [2]. Wang M, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 Mar;32(3):1537-1549. |
|
| Cas No. | 1374853-91-4 | SDF | |
| 别名 | 派姆单抗,帕博利珠单抗,Lambrolizumab; MK-3475 | ||
| 分子式 | 分子量 | 146266.23 | |
| 溶解度 | 储存条件 | Store at -80°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0068 mL | 0.0342 mL | 0.0684 mL |
| 5 mM | 0.0014 mL | 0.0068 mL | 0.0137 mL |
| 10 mM | 0.0007 mL | 0.0034 mL | 0.0068 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet